Document Detail


Alcohol consumption and breast cancer risk among postmenopausal women following the cessation of hormone therapy use: the California Teachers Study.
MedLine Citation:
PMID:  22832206     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Alcohol consumption increases breast cancer risk, but its effect may be modified by hormone therapy (HT) use, such that exposure to both may be synergistic. Because many women stopped taking HT after mid-2002, it is important to quantify risks associated with alcohol consumption in the context of HT cessation, as these risks may be more relevant to cancer prevention efforts today.
METHODS: Among 40,680 eligible postmenopausal California Teachers Study cohort participants, 660 were diagnosed with invasive breast cancer before 2010. Multivariate Cox proportional hazards regression models were used to estimate relative risks (RR) and 95% confidence intervals (CI).
RESULTS: Increased breast cancer risk associated with alcohol consumption was observed among postmenopausal women who were current HT users [RR, 1.60; 95% confidence interval (CI), 1.13-2.26 and RR, 2.11; 95% CI, 1.41-3.15 for <20 and ≥20 g/d of alcohol], with risks being similar by HT preparation. Alcohol did not increase risk among women who had stopped using HT within 3 years or 3 to 4 years before completing the follow-up questionnaire or in the more distant past. Results were similar for estrogen receptor positive (ER+) and ER+PR+ progesterone receptors positive (PR+) tumors; while power was limited, no increase in risk was observed for ER- tumors.
CONCLUSIONS: Following the cessation of HT use, alcohol consumption is not significantly associated with breast cancer risk, although a nonsignificant increased risk was observed among women who never used HT.
IMPACT: Our findings confirm that concurrent exposure to HT and alcohol has a substantial adverse impact on breast cancer risk. However, after HT cessation, this risk is reduced.
Authors:
Pamela L Horn-Ross; Alison J Canchola; Leslie Bernstein; Christina A Clarke; James V Lacey; Susan L Neuhausen; Peggy Reynolds; Giske Ursin
Related Documents :
22341886 - Modeling the risk: innovative approaches to understand and quantify the risk of severe ...
9100086 - Validation of estrogen status as an independent predictor of coronary artery disease pr...
19424986 - Reproductive factors, exogenous estrogen use, and risk of parkinson's disease.
7404306 - Estrogens and postoperative thrombosis evaluated by the radioactive iodine method.
19337536 - Cardiometabolic risk in psoriasis: differential effects of biologic agents.
16097046 - Vitamin d receptor gene tru9i polymorphism and risk for incidental sporadic colorectal ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.     Date:  2012-07-25
Journal Detail:
Title:  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology     Volume:  21     ISSN:  1538-7755     ISO Abbreviation:  Cancer Epidemiol. Biomarkers Prev.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-08     Completed Date:  2013-07-10     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  9200608     Medline TA:  Cancer Epidemiol Biomarkers Prev     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2006-13     Citation Subset:  IM    
Copyright Information:
©2012 AACR.
Affiliation:
Cancer Prevention Institute of California, 2201 Walnut Ave., Suite 300, Fremont, CA 94538. pam@cpic.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Alcohol Drinking / adverse effects,  epidemiology*
Breast Neoplasms / epidemiology*,  etiology
California / epidemiology
Cohort Studies
Estrogen Replacement Therapy / statistics & numerical data
Female
Humans
Middle Aged
Postmenopause
Proportional Hazards Models
Questionnaires
Risk Assessment
Risk Factors
Grant Support
ID/Acronym/Agency:
HHSN261201000034C//PHS HHS; HHSN261201000035C//PHS HHS; HHSN261201000036C//PHS HHS; K05 CA136967/CA/NCI NIH HHS; R01 CA077398/CA/NCI NIH HHS; R01 CA77398/CA/NCI NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relationship between the Head Deviation Angle and Hemineglect in Patients with Right Hemisphere Stro...
Next Document:  SOX2 antoantibodies as non-invasive serum biomarker for breast carcinoma.